UBS AM
MBX

UBS AM’s MBX Biosciences MBX Stock Holding History

UBS AM’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
21,344
+14,106
+195% +$493K ﹤0.01% 2293
2026
Q1 		$216K Buy
7,238
+7,138
+7,138% +$243K ﹤0.01% 2718
2025
Q4 		$3.15K Buy
+100
New +$2.43K ﹤0.01% 3063

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

UBS AM's MBX Position: Q2 2026 in Review

UBS AM increased its MBX Biosciences (MBX) stake by 195% in Q2 2026, buying an estimated $493K and bringing the position to 21,344 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

UBS AM first reported a position in MBX in Q4 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • UBS AM held 21,344 shares of MBX Biosciences worth $1.18M as of Q2 2026.
  • UBS AM bought 14,106 MBX Biosciences shares in Q2 2026, an estimated $493K.
  • MBX Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2293 holding.
  • UBS AM first reported a position in MBX Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.